S&P 500   3,110.40 (+0.44%)
DOW   27,898.54 (+0.42%)
QQQ   202.50 (+0.53%)
CGC   15.66 (-1.14%)
BABA   184.84 (+1.11%)
GE   11.44 (+1.33%)
T   39.11 (+0.41%)
F   8.94 (+1.71%)
ACB   3.08 (-6.38%)
DIS   146.30 (-0.58%)
S&P 500   3,110.40 (+0.44%)
DOW   27,898.54 (+0.42%)
QQQ   202.50 (+0.53%)
CGC   15.66 (-1.14%)
BABA   184.84 (+1.11%)
GE   11.44 (+1.33%)
T   39.11 (+0.41%)
F   8.94 (+1.71%)
ACB   3.08 (-6.38%)
DIS   146.30 (-0.58%)
S&P 500   3,110.40 (+0.44%)
DOW   27,898.54 (+0.42%)
QQQ   202.50 (+0.53%)
CGC   15.66 (-1.14%)
BABA   184.84 (+1.11%)
GE   11.44 (+1.33%)
T   39.11 (+0.41%)
F   8.94 (+1.71%)
ACB   3.08 (-6.38%)
DIS   146.30 (-0.58%)
S&P 500   3,110.40 (+0.44%)
DOW   27,898.54 (+0.42%)
QQQ   202.50 (+0.53%)
CGC   15.66 (-1.14%)
BABA   184.84 (+1.11%)
GE   11.44 (+1.33%)
T   39.11 (+0.41%)
F   8.94 (+1.71%)
ACB   3.08 (-6.38%)
DIS   146.30 (-0.58%)
Log in

Acura Pharmaceuticals Stock Price, Forecast & Analysis (OTCMKTS:ACUR)

$0.45
+0.03 (+7.91 %)
(As of 11/15/2019 08:59 AM ET)
Today's Range
$0.40
Now: $0.45
$0.45
50-Day Range
$0.29
MA: $0.35
$0.45
52-Week Range
$0.06
Now: $0.45
$0.63
Volume1,461 shs
Average Volume5,649 shs
Market Capitalization$9.59 million
P/E RatioN/A
Dividend YieldN/A
Beta1.49
Acura Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the research, development, and commercialization of technologies and products to address medication abuse and misuse. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolOTCMKTS:ACUR
Previous SymbolNASDAQ:ACUR
CUSIP00509L70
Phone847-705-7709

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$410,000.00
Book Value($0.17) per share

Profitability

Net Income$-3,840,000.00
Net Margins-1,124.01%

Miscellaneous

Employees14
Market Cap$9.59 million
Next Earnings Date11/26/2019 (Estimated)
OptionableNot Optionable

Receive ACUR News and Ratings via Email

Sign-up to receive the latest news and ratings for ACUR and its competitors with MarketBeat's FREE daily newsletter.


Acura Pharmaceuticals (OTCMKTS:ACUR) Frequently Asked Questions

What is Acura Pharmaceuticals' stock symbol?

Acura Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ACUR."

How were Acura Pharmaceuticals' earnings last quarter?

Acura Pharmaceuticals, Inc. (OTCMKTS:ACUR) released its quarterly earnings data on Tuesday, October, 1st. The specialty pharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter. The specialty pharmaceutical company earned $0.07 million during the quarter. View Acura Pharmaceuticals' Earnings History.

When is Acura Pharmaceuticals' next earnings date?

Acura Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, November 26th 2019. View Earnings Estimates for Acura Pharmaceuticals.

Has Acura Pharmaceuticals been receiving favorable news coverage?

Media stories about ACUR stock have trended somewhat negative on Friday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Acura Pharmaceuticals earned a media sentiment score of -1.4 on InfoTrie's scale. They also gave news headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Acura Pharmaceuticals.

Who are some of Acura Pharmaceuticals' key competitors?

What other stocks do shareholders of Acura Pharmaceuticals own?

Who are Acura Pharmaceuticals' key executives?

Acura Pharmaceuticals' management team includes the folowing people:
  • Mr. Robert B. Jones, CEO, Pres & Director (Age 60)
  • Mr. Peter A. Clemens, Sr. VP, CFO & Sec. (Age 66)
  • Mr. James F. Emigh, VP of Corp. Devel. (Age 63)
  • Mr. Robert A. Seiser Ph.D., VP, Treasurer & Corp. Controller (Age 55)

How do I buy shares of Acura Pharmaceuticals?

Shares of ACUR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Acura Pharmaceuticals' stock price today?

One share of ACUR stock can currently be purchased for approximately $0.45.

How big of a company is Acura Pharmaceuticals?

Acura Pharmaceuticals has a market capitalization of $9.59 million and generates $410,000.00 in revenue each year. Acura Pharmaceuticals employs 14 workers across the globe.View Additional Information About Acura Pharmaceuticals.

What is Acura Pharmaceuticals' official website?

The official website for Acura Pharmaceuticals is http://www.acurapharm.com/.

How can I contact Acura Pharmaceuticals?

Acura Pharmaceuticals' mailing address is 616 N. NORTH COURT SUITE 120, PALATINE IL, 60067. The specialty pharmaceutical company can be reached via phone at 847-705-7709 or via email at [email protected]


MarketBeat Community Rating for Acura Pharmaceuticals (OTCMKTS ACUR)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  178 (Vote Outperform)
Underperform Votes:  139 (Vote Underperform)
Total Votes:  317
MarketBeat's community ratings are surveys of what our community members think about Acura Pharmaceuticals and other stocks. Vote "Outperform" if you believe ACUR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACUR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/15/2019 by MarketBeat.com Staff

Featured Article: Intrinsic Value

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel